---
run_id: halo-evidence-vs-diagnosis-validation-v8-generic-advice-prompted-07
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v8
benchmark_version: halo-evidence-vs-diagnosis-validation-v8-v1
model_condition: generic_advice_prompted
run_number: 7
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 705
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
condition_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
output_file: model-outputs/generic_advice_prompted-07.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 07)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v8-v1`, condition `generic_advice_prompted`, run 7 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 705, on the frozen condition packet.

## Output

I recommend that you advise the CEO to commit to the **targeted evidence pass**.

### Reasoning
You are currently facing a classic "false positive" in B2B SaaS: your lagging indicators (revenue and renewals) look great, but your leading indicators (front-line user retention and auditor acceptance) are flashing red.

The "upbeat story" for the board is built on a foundation of artificial stimulants. The 18% expansion revenue is largely a result of discounting to pull forward renewals, not a reflection of organic value creation. More concerning is the "usage" data: a 44% increase driven by "champions" preparing for meetings is a vanity metric. The real metric is the 31% first-week retention among front-line reviewers. In a workflow tool, if the person doing the actual work abandons the tool, the product is not "sticky"—it is a liability.

If you scale broadly now (Option 1), you are essentially betting the company's annual budget on a "black box" that your users cannot explain to their regulators and your front-line staff find useless. You will likely see a massive churn event in 12 months when the early-renewal discounts expire and the "Review Assist" novelty wears off.

If you narrow the focus to regulated compliance (Option 3) immediately, you are pivoting based on a symptom (insurance accounts) without knowing if the "explainability" problem is universal or segment-specific.

The evidence pass is the only option that treats the current revenue bump as a *hypothesis* rather than a *fact*. It allows you to decouple the "Sales momentum" from the "Product value" to see if there is actually a wedge there.

### The Trade-offs
By choosing the evidence pass, you are sacrificing **short-term perceived momentum**. You will have to tell the CEO—and potentially the board—that the "upbeat story" requires a cautionary footnote. You are intentionally slowing down the sales engine and risking the frustration of a sales leadership team that believes they have found a goldmine. You are trading a potential (but fragile) revenue spike for operational certainty.

### The Strongest Reason Against This Recommendation
**The Momentum Trap.** In mid-market B2B, "perceived" success often creates "actual" success. By pausing discounts and instrumenting behavior, you risk killing the psychological momentum of the sales team and the "customer-obsessed" narrative currently pleasing the board. If your competitors are scaling a similar feature aggressively, a three-month "evidence pass" could result in a loss of market share that no amount of "explainability" can recover. You risk looking like a "product perfectionist" who is obstructing a revenue win.

### Observable Evidence That Would Change My Mind
I would move from the "Evidence Pass" to "Scale Broadly" if you can produce evidence of **organic, non-discounted expansion.**

Specifically: if you find a cohort of customers who *did not* receive the six-month discount, *did not* receive the "top priority" pitch from account managers, yet still showed a front-line reviewer retention rate of >60% and requested the feature proactively. If the value is being pulled from the customer rather than pushed by Sales, the risk of scaling is significantly lower.
